Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jones Lang LaSalle Inc (JLL) vs Revvity Inc (RVTY) Price & Performance

Jones Lang LaSalle IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Jones Lang LaSalle Inc vs Revvity Inc — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Revvity Inc for 12 Days on average.

JLLRVTY
Market Cap
$13.95B$16.98B
Volume
457,4621,456,900
Sector
Real EstateHealth
52-Week High
$392.79$157.36
52-Week Low
$280.16$82.26
Typical Hold Time
71 Days12 Days
Enterprise Value
$16.71B$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jones Lang LaSalle Inc

JLL trades at $299.87, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $5.26 exceeding the $4.56 estimate. Revenue grew to $26.12B in 2025, and net income margin improved to 3.64%. Recent news highlights acquisitions and financing deals, such as the $406M Trammell Crow Center financing announced on September 24, 2026.

The outlook is positive, supported by analyst consensus price target of $450.50 and 58.33% buy ratings. Key opportunities include growth in data center operations and proprietary platforms, while risks involve real estate market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and P/S of 0.53, but investors should monitor debt levels and economic cycles.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JLL
100% Buy0% Sell
Avg holding period · 71 Days
RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Jones Lang LaSalle Inc

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.

Read more on JLL →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →